English – Page 856 – TechStock²

Praxis Precision stock rises as $575 million share sale clears at $260

NEW YORK, Jan 7, 2026, 12:02 PM EST — Regular session Praxis Precision Medicines shares rose about 6% on Wednesday after the biotech priced a $575 million public offering overnight, even as the deal came at a discount to the prior close. GlobeNewswire The Boston-based company late Tuesday set the offering at $260 per share for 2.212 million shares, and gave underwriters a 30-day option to buy up to 331,800 more shares. The deal is expected to close on or about Jan. 8, the company said. GlobeNewswire The stock was last at about $289.5 in midday trading, versus Tuesday’s close

7 January 2026

Business·Company News·Finance·Investing·NASDAQ:PRAX·Stock Market

Exxon Mobil stock slides as Trump’s Venezuela oil plan drags crude, filing due after close

NEW YORK, Jan 7, 2026, 11:38 EST — Regular session Exxon Mobil Corporation shares fell on Wednesday as oil prices slid and traders weighed fresh signals on Venezuelan supply. The stock was down $1.34, or 1.1%, at $119.71, after touching an intraday low of $118.96. Chevron was little changed while ConocoPhillips fell about 1%. The drop tracked crude after U.S. President Donald Trump said Venezuela would “turn over” between 30 million and 50 million barrels of sanctioned oil to the United States. Brent was down about 0.7% near $60 a barrel and U.S. West Texas Intermediate was off about 1.3%

7 January 2026

Financial News·NYSE:XOM·Oil Industry·Stock Market

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

New York, January 7, 2026, 11:41 EST — Regular session. Eli Lilly and Company shares were up 3.3% at $1,099.44 in late morning trade, pushing back toward the $1,100 level as investors cheered fresh deal chatter around the drugmaker’s pipeline. (https://www.reuters.com/markets/companies/LLY.N/) The lift matters now because the market is watching how Lilly defends its growth run while competitors push pill versions of obesity drugs and pricing stays in flux. Investors have rewarded companies that can keep adding late-stage shots on goal without derailing margins. The Wall Street Journal reported Lilly is in advanced talks to buy Ventyx Biosciences for more

7 January 2026

Business Trends·Investment Insights·NYSE:LLY·Pharma News·Stock Market

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

New York, Jan 7, 2026, 11:50 a.m. EST — Regular session Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort. The agreement matters because it puts near-term cash on the table for a clinical-stage biotech and suggests its intellectual property has value beyond its own pipeline, at a moment when markets are quick to price any edge in the crowded GLP-1 weight-loss race. A Form 8-K filing showed the company’s Gasherbrum Bio

7 January 2026

Biotechnology·Market News·NASDAQ:GPX·Stock Analysis

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

NEW YORK, Jan 7, 2026, 11:43 EST — Regular session Bloom Energy Corp (NYSE: BE) shares rose 8.1% to $111.38 on Wednesday, lifting off an intraday low of $100.87, as investors refocused on a new $600 million bank line and a large fuel-cell microgrid purchase linked to Quanta. The stock hit an intraday high of $111.41 and traded more than 8.3 million shares by late morning, keeping the $100 level in play for traders after the early slide. The move matters because Bloom has become a sensitive read-through on on-site power demand, a corner of the market that has drawn

7 January 2026

Business Analysis·Financial News·Investing·NYSE:BE·Real Estate·Stock Market

Oracle stock (ORCL) barely moves as Jefferies sticks with $400 target

New York, January 7, 2026, 11:40 ET — Regular session Oracle Corp shares slipped 0.2% to $193.44 in late-morning trading on Wednesday, after Jefferies reiterated a Buy rating and kept a $400 price target in a 2026 software outlook. Jefferies analyst Brent Thill said OpenAI accounts for 57% of Oracle’s contract backlog and argued the stock can rebound after a roughly 40% slide tied to worry about AI spending and debt. Investors The call matters because Oracle has become a test case for how much the market will pay for AI infrastructure inside a mature software name. Investors want proof

7 January 2026

Analyst Ratings·Financial News·Investment·NASDAQ:ORCL·Oracle·Stock Market

Chevron stock edges higher as $22 billion Lukoil-bid talk collides with Venezuela supply headlines

New York, Jan 7, 2026, 11:28 EST — Regular session Chevron Corp shares inched up on Wednesday as investors digested a report that private equity group Quantum Energy Partners is working on a bid that could involve Chevron for the international assets of Russia’s Lukoil, even as weaker oil prices kept a lid on energy stocks more broadly. The stock was up 0.1% at $156.68 by late morning in New York, after trading between $155.19 and $159.60; Exxon Mobil was down about 1.2%, ConocoPhillips fell 1.3% and Occidental Petroleum slid 1.5%. Reuters The timing matters. A possible transaction for sanctioned-era

7 January 2026

Energy Sector·NYSE:CVX·Stock Market

AppLovin (APP) stock rises as Piper Sandler sticks with $800 target and BofA keeps $860 view

New York, January 7, 2026, 11:36 EST — Regular session AppLovin (APP.O) shares rose about 2% on Wednesday, building on a choppy start to the year as fresh analyst notes kept attention on the company’s push into e-commerce advertising. The stock was up at $629.57, while the S&P 500 was little changed and the Nasdaq-100 ETF edged higher; rival Trade Desk fell. The move matters because AppLovin’s next leg is still being priced in. Bulls are betting the company can broaden beyond mobile-game ads into web and e-commerce budgets, and the next earnings call is expected to put real numbers

7 January 2026

Analyst Ratings·Financial News·Investment·NASDAQ:APP·Stock Market·Technology Stocks

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded. Why it matters now: the move builds on Tuesday’s 22% gain and keeps Regencell near the top of the day’s high-volatility names, even by small-cap standards. The stock closed at $33.03 on Tuesday after trading as high as $35.68, following a $27.00 close on Monday. StockAnalysis The

7 January 2026

Biotech Stocks·NASDAQ:RGC·Stock Market

SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

NEW YORK, Jan 7, 2026, 11:26 (EST) — Regular session SoFi Technologies shares were down about 1.4% at $26.61 by 11:26 a.m. EST on Wednesday, extending recent weakness as investors absorbed fresh details on stock sold into the market. A regulatory filing showed the underwriters of SoFi’s December share sale exercised their option to buy additional stock, and the company completed that extra issuance on Jan. 5. The “greenshoe” option — a standard clause that lets banks buy more shares — pushed total shares sold in the offering to 57,754,660 at $27.50 each, with Goldman Sachs, BofA Securities, Citigroup, Deutsche

7 January 2026

Earnings Reports·Fintech·Investment News·NASDAQ:SOFI·Stock Market

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares. The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on a single late-stage drug program. Its American depositary shares, or ADSs, are U.S.-traded certificates that represent ownership of a foreign company’s shares. Abivax is developing obefazimod, an oral treatment candidate for ulcerative colitis, a chronic inflammatory bowel disease. The company

7 January 2026

Biotech News·Financial Analysis·Investing·Nasdaq·NASDAQ:ABVX·Stock Market

UMC stock jumps near 10% after December sales update as January earnings near

NEW YORK, January 7, 2026, 11:07 EST — Regular session United Microelectronics’ U.S.-listed shares surged on Wednesday, pushing the Taiwan chipmaker to a fresh 52-week high and putting the stock among the session’s top semiconductor gainers. UMC was up about 9.7% at $8.91 in late morning trade. The move matters because UMC’s monthly sales are one of the first hard reads on foundry demand going into 2026, when investors are trying to pin down whether the industry has truly worked through excess inventory. Chip stocks have also caught a bid this week after upbeat signals elsewhere in the sector, including

7 January 2026

Earnings Reports·Financial News·Investment Analysis·NYSE:UMC·Semiconductor Industry·Stock Market

Previous 1 … 854 855 856 857 858 … 2,707 Next

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

7 February 2026

Macquarie Group shares fell 2.17% to A$207.83 Friday, marking a third straight decline as the ASX 200 slid 2%. Australia’s regulator trimmed liquidity requirements for Macquarie Bank after improvements in controls. Macquarie Asset Management announced two UK utility deals, including full ownership of Last Mile Infrastructure and the purchase of Energy Assets Group. Investors await Tuesday’s operational briefing.

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026

LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:05 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026

Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026

Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.